232 related articles for article (PubMed ID: 31774199)
21. Transglutaminase 2 Inhibition Reverses Mesenchymal Transdifferentiation of Glioma Stem Cells by Regulating C/EBPβ Signaling.
Yin J; Oh YT; Kim JY; Kim SS; Choi E; Kim TH; Hong JH; Chang N; Cho HJ; Sa JK; Kim JC; Kwon HJ; Park S; Lin W; Nakano I; Gwak HS; Yoo H; Lee SH; Lee J; Kim JH; Kim SY; Nam DH; Park MJ; Park JB
Cancer Res; 2017 Sep; 77(18):4973-4984. PubMed ID: 28754668
[TBL] [Abstract][Full Text] [Related]
22. MALT1 Phosphorylation Controls Activation of T Lymphocytes and Survival of ABC-DLBCL Tumor Cells.
Gehring T; Erdmann T; Rahm M; Graß C; Flatley A; O'Neill TJ; Woods S; Meininger I; Karayel O; Kutzner K; Grau M; Shinohara H; Lammens K; Feederle R; Hauck SM; Lenz G; Krappmann D
Cell Rep; 2019 Oct; 29(4):873-888.e10. PubMed ID: 31644910
[TBL] [Abstract][Full Text] [Related]
23. An allosteric MALT1 inhibitor is a molecular corrector rescuing function in an immunodeficient patient.
Quancard J; Klein T; Fung SY; Renatus M; Hughes N; Israël L; Priatel JJ; Kang S; Blank MA; Viner RI; Blank J; Schlapbach A; Erbel P; Kizhakkedathu J; Villard F; Hersperger R; Turvey SE; Eder J; Bornancin F; Overall CM
Nat Chem Biol; 2019 Mar; 15(3):304-313. PubMed ID: 30692685
[TBL] [Abstract][Full Text] [Related]
24. Function and targeting of MALT1 paracaspase in cancer.
O'Neill TJ; Tofaute MJ; Krappmann D
Cancer Treat Rev; 2023 Jun; 117():102568. PubMed ID: 37126937
[TBL] [Abstract][Full Text] [Related]
25. Qki deficiency maintains stemness of glioma stem cells in suboptimal environment by downregulating endolysosomal degradation.
Shingu T; Ho AL; Yuan L; Zhou X; Dai C; Zheng S; Wang Q; Zhong Y; Chang Q; Horner JW; Liebelt BD; Yao Y; Hu B; Chen Y; Fuller GN; Verhaak RG; Heimberger AB; Hu J
Nat Genet; 2017 Jan; 49(1):75-86. PubMed ID: 27841882
[TBL] [Abstract][Full Text] [Related]
26. Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth.
Fontán L; Qiao Q; Hatcher JM; Casalena G; Us I; Teater M; Durant M; Du G; Xia M; Bilchuk N; Chennamadhavuni S; Palladino G; Inghirami G; Philippar U; Wu H; Scott DA; Gray NS; Melnick A
J Clin Invest; 2018 Oct; 128(10):4397-4412. PubMed ID: 30024860
[TBL] [Abstract][Full Text] [Related]
27. TRAF6 controls T cell homeostasis by maintaining the equilibrium of MALT1 scaffolding and protease functions.
O'Neill TJ; Gewies A; Seeholzer T; Krappmann D
Front Immunol; 2023; 14():1111398. PubMed ID: 36761777
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological inhibition of MALT1 protease activity suppresses endothelial activation via enhancing MCPIP1 expression.
Li Y; Huang S; Huang X; Li X; Falcon A; Soutar A; Bornancin F; Jiang Z; Xin HB; Fu M
Cell Signal; 2018 Oct; 50():1-8. PubMed ID: 29913212
[TBL] [Abstract][Full Text] [Related]
29. MALT1-dependent cleavage of CYLD promotes NF-κB signaling and growth of aggressive B-cell receptor-dependent lymphomas.
Minderman M; Lantermans HC; Grüneberg LJ; Cillessen SAGM; Bende RJ; van Noesel CJM; Kersten MJ; Pals ST; Spaargaren M
Blood Cancer J; 2023 Mar; 13(1):37. PubMed ID: 36922488
[TBL] [Abstract][Full Text] [Related]
30. Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K/AKT/mTOR signaling pathway.
Miao L; Jiang Z; Wang J; Yang N; Qi Q; Zhou W; Feng Z; Li W; Zhang Q; Huang B; Chen A; Zhang D; Zhao P; Li X
Oncol Rep; 2019 Aug; 42(2):605-614. PubMed ID: 31233190
[TBL] [Abstract][Full Text] [Related]
31. MALT1 inhibitors prevent the development of DSS-induced experimental colitis in mice via inhibiting NF-κB and NLRP3 inflammasome activation.
Liu W; Guo W; Hang N; Yang Y; Wu X; Shen Y; Cao J; Sun Y; Xu Q
Oncotarget; 2016 May; 7(21):30536-49. PubMed ID: 27105502
[TBL] [Abstract][Full Text] [Related]
32. Proteolytic Activity of the Paracaspase MALT1 Is Involved in Epithelial Restitution and Mucosal Healing.
Wittner L; Wagener L; Wiese JJ; Stolzer I; Krug SM; Naschberger E; Jackstadt R; Beyaert R; Atreya R; Kühl AA; Sturm G; Gonzalez-Acera M; Patankar JV; Becker C; Siegmund B; Trajanoski Z; Winner B; Neurath MF; Schumann M; Günther C
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108564
[TBL] [Abstract][Full Text] [Related]
33. Synergistic anti-breast cancer effect of pulsatilla saponin D and camptothecin through interrupting autophagic-lysosomal function and promoting p62-mediated ubiquitinated protein aggregation.
Wang K; Tu Y; Wan JB; Chen M; He C
Carcinogenesis; 2020 Jul; 41(6):804-816. PubMed ID: 31504230
[TBL] [Abstract][Full Text] [Related]
34. MALT1 paracaspase is overexpressed in hepatocellular carcinoma and promotes cancer cell survival and growth.
Kurden-Pekmezci A; Cakiroglu E; Eris S; Mazi FA; Coskun-Deniz OS; Dalgic E; Oz O; Senturk S
Life Sci; 2023 Jun; 323():121690. PubMed ID: 37059355
[TBL] [Abstract][Full Text] [Related]
35. NFAT1-Mediated Regulation of NDEL1 Promotes Growth and Invasion of Glioma Stem-like Cells.
Jiang Y; Song Y; Wang R; Hu T; Zhang D; Wang Z; Tie X; Wang M; Han S
Cancer Res; 2019 May; 79(10):2593-2603. PubMed ID: 30940662
[TBL] [Abstract][Full Text] [Related]
36. Enhanced translation expands the endo-lysosome size and promotes antigen presentation during phagocyte activation.
Hipolito VEB; Diaz JA; Tandoc KV; Oertlin C; Ristau J; Chauhan N; Saric A; Mclaughlan S; Larsson O; Topisirovic I; Botelho RJ
PLoS Biol; 2019 Dec; 17(12):e3000535. PubMed ID: 31800587
[TBL] [Abstract][Full Text] [Related]
37. MALT1 activation by TRAF6 needs neither BCL10 nor CARD11.
Bardet M; Seeholzer T; Unterreiner A; Woods S; Krappmann D; Bornancin F
Biochem Biophys Res Commun; 2018 Nov; 506(1):48-52. PubMed ID: 30336982
[TBL] [Abstract][Full Text] [Related]
38. Role of Malt1 protease activity in pathogenesis of inflammatory disorders mediated by FcγR signaling.
Nakamura Y; Yokoyama K; Igaki K; Tsuchimori N
Int Immunopharmacol; 2018 Mar; 56():193-196. PubMed ID: 29414650
[TBL] [Abstract][Full Text] [Related]
39. Lysosomes in glioblastoma: pump up the volume.
Jacobs KA; Maghe C; Gavard J
Cell Cycle; 2020 Sep; 19(17):2094-2104. PubMed ID: 32723137
[TBL] [Abstract][Full Text] [Related]
40. GRK2 suppresses lymphomagenesis by inhibiting the MALT1 proto-oncoprotein.
Cheng J; Klei LR; Hubel NE; Zhang M; Schairer R; Maurer LM; Klei HB; Kang H; Concel VJ; Delekta PC; Dang EV; Mintz MA; Baens M; Cyster JG; Parameswaran N; Thome M; Lucas PC; McAllister-Lucas LM
J Clin Invest; 2020 Feb; 130(2):1036-1051. PubMed ID: 31961340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
